Lv6
2400 积分 2023-10-16 加入
Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study
2个月前
已完结
Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells
2个月前
已完结
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies
3个月前
已完结
The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa
3个月前
已完结
A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody® molecule
3个月前
已完结
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
3个月前
已完结
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
3个月前
已完结
Anti‐IL17 Secukinumab in hidradenitis suppurativa: A long‐term drug survival analysis
3个月前
已完结
Real‐world adalimumab survival and discontinuation factors in hidradenitis suppurativa
3个月前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
3个月前
已完结
皖公网安备34019202002308
